DR-0201是一款潜在“first-in-class”的CD20靶向双特异性抗体。它通过靶向并激活特定的组织驻留和迁移髓系细胞，通过靶向吞噬作用诱导深度B细胞耗竭。最近在自身免疫疾病中的早期临床研究数据表明，深度B细胞耗竭可能具有重置适应性免疫系统的潜力，从而在如红斑狼疮等难治性B细胞介导的自身免疫疾病患者中实现持久的无治疗缓解。DR-0201目前正在两项1期临床试验中接受评估。

Just over 25 years ago, MYC, the human homologue of a retroviral oncogene, was identified. Since that time, MYC research has been intense and the advances impressive. On reflection, it is ...

In summary, L-MYC and N-MYC expression in tumor tissue ... Write to [email protected] Monte Rosa Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics Inc ... the oncogenic functions of the ‘holy grail’ targets MYC and beta catenin through novel mechanisms of action ...

These c-mods alter the oncogenic functions of the ‘holy grail’ targets MYC and beta catenin through ... About Dewpoint Therapeutics Dewpoint is the leading biotech company in the application ...

In December 2024, Monte Rosa Therapeutics, Inc. provided an update on its ongoing Phase I/II open-label, multicenter trial of MRT-2359 in patients with MYC-driven solid tumors. MRT-2359 is an ...